Detalhe da pesquisa
1.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer
; 23(1): 708, 2023 Jul 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507657
2.
Prognostic Role of Neutrophil, Monocyte and Platelet to Lymphocyte Ratios in Advanced Ovarian Cancer According to the Time of Debulking Surgery.
Int J Mol Sci
; 24(14)2023 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37511180
3.
A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors.
Radiology
; 299(1): 109-119, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33497314
4.
Tumor-Associated Microbiome: Where Do We Stand?
Int J Mol Sci
; 22(3)2021 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33535583
5.
Turning up the heat on non-immunoreactive tumours: opportunities for clinical development.
Lancet Oncol
; 21(9): e419-e430, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888471
6.
Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC.
Lancet Oncol
; 23(4): e157, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35358457
7.
Dual inhibition of MEK and PI3Kß/δ-a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer.
Front Pharmacol
; 15: 1331648, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38318136
8.
Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.
Clin Cancer Res
; 29(12): 2250-2265, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36749875
9.
Low-dose irradiation for reversing immunotherapy resistance: how to translate?
J Immunother Cancer
; 10(7)2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835490
10.
Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies.
J Immunother Cancer
; 10(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35217575
11.
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
Cancer Discov
; 12(1): 108-133, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34479871
12.
A promising platform for predicting toxicity.
Elife
; 102021 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34558412
13.
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials.
Eur J Cancer
; 155: 168-178, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34385069
14.
OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors.
Clin Cancer Res
; 27(2): 460-472, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33148673
15.
High versus low dose irradiation for tumor immune reprogramming.
Curr Opin Biotechnol
; 65: 268-283, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32882511
16.
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
J Immunother Cancer
; 8(2)2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32847987
17.
PSA Kinetics as Prognostic Markers of Overall Survival in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone Acetate.
Cancer Manag Res
; 12: 10251-10260, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33116879
18.
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti-PD-1 antibody, in patients with advanced solid tumors.
J Immunother Cancer
; 8(1)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32179633
19.
Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Clin Cancer Res
; 26(8): 1846-1855, 2020 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31757877
20.
Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Clin Cancer Res
; 25(11): 3210-3219, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30670489